PHOTO RX

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项随机、非盲、对照研究的主要目的是确定极低出生体重（ELBW）婴儿在18-22个月时死亡或神经发育障碍的发生率是否因接受积极或保守光疗而不同。将比较两个治疗组之间的血清胆红素峰值、光疗开始时的年龄、光疗持续时间和进行的交换输血次数。此外，将不良结局与胆红素暴露的各种指标（如血清总胆红素峰值、间接血清胆红素峰值、胆红素值超过特定水平的持续时间）进行比较，以评估哪种指标最能预测不良结局。还将研究不良结局的预测因子是否因治疗组而异。次要目的是确定使用积极或保守光疗方案是否会导致18-22个月时死亡、脑瘫、Bayley II发育评分、失明和耳聋的差异。一项次要研究探讨了未结合胆红素是否是比总胆红素浓度更好的神经发育结局预测因子。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this randomized, unmasked, controlled study is to determine whether the incidence of death or neurodevelopmental impairment at 18-22 months among extremely low birth weight (ELBW) infants differs according to whether they were treated with aggressive or conservative phototherapy. Peak serum bilirubin, age at inception of phototherapy, duration of phototherapy, and number of exchange transfusions performed will be compared between the two treatment groups. In addition, adverse outcomes will be compared to various measures of bilirubin exposure such as peak total serum bilirubin, peak indirect serum bilirubin, duration of bilirubin values exceeding a particular level to assess which measure best predicts adverse outcome. Whether the predictors of adverse outcome differ by treatment group will also be investigated. Secondary objectives are to determine whether the use of an aggressive or conservative phototherapy regimen results in differences at 18-22 months in death, cerebral palsy, Bayley II developmental scores, blindness, and deafness. A secondary study addresses if unbound bilirubin is a better predictor of neurodevelopmental outcome than total bilirubin concentration.